ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF (BATS: MSTU)

Últimas noticias sobre ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF (BATS:MSTU)

Technology

The Fund will enter into one or more swap agreements with major global financial institutions whereby the Fund and the global financial institution will agree to exchange the return earned on an investment by the Fund in MSTR that is equal, on a daily basis, to 200% of the value of the Funds net assets. The Adviser attempts to consistently apply leverage to obtain MSTR exposure for the Fund equal to 200% of the value of its net assets and expects to rebalance the Funds holdings daily to maintain such exposure. As a result of its investment strategies, the Fund will be concentrated in the industry to which MSTR is assigned (i.e., hold 25% or more of its total assets in investments that provide leveraged exposure in the industry to which MSTR is assigned). As of the date of this prospectus, MSTR is assigned to the information technology sector and the software industry.

Microstrategy Inc Cl A

T-Rex 2X Long MSTR Daily Target ETF

Equities

Large Cap

News

Offerings

Movers

CRPT

MSTR

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF

MSTU

MicroStrategy anuncia la emisión de 2,5M de acciones preferentes perpetuas de Serie A para financiar compra de BTC y capital circulante.

MicroStrategy (MSTR) emite acciones preferentes y ajusta su estrategia financiera

Orion Energy Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) (<a href="https://www.globenewswire.com/Tracker?data=US_Yxm5yci6nTw53oilmiImZq9yEXerXpM2lblSMGoXuTNzSIBf0B-tVHjPgDsKn6NVkrtEq8IpyCXznGOHQq1UmCGhmd-qFlBmQjHkiOZ4=">Orion Lighting</a>), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced that it has secured LED lighting and Electrical Infrastructure engagements representing revenue of up to $7M in FY 2026 from long-time automotive industry customers in North America.
Orion's automotive-industry engagements — consisting of deployments and upgrades of LED Lighting and Electrical Infrastructure, along with ongoing managed services — have begun in several manufacturing and distribution facilities in North America. The facilities are owned primarily by three major automotive industry customers, including two global leaders that are among the most prominent automakers in North America. The engagements are part of an ongoing updating of the LED lighting and electrical infrastructure of manufacturing and distribution facilities operated by all three customers. The contracts illustrate Orion's long-term incumbency as a key lighting and electrical contracting provider to the top tier of North America's automakers.
Orion Chief Executive Officer Sally Washlow plans to review the company's expanding automotive market leadership and growing new-business pipeline on its first quarter conference call on Wednesday, August 6, 2025. With Ms. Washlow now in her first full quarter as CEO, Orion expects to approach or achieve positive adjusted EBITDA on revenue growing to approximately $84M in FY'26.

OESX

Orion Energy Systems Secures LED Lighting And Electrical Infrastructure Engagements Representing Revenue Of Up To $7M In FY26 From North America Customers

DA Davidson analyst Kevin Fitzsimmons maintains Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) with a Buy and raises the price target from $78 to $81.

Price Target

Analyst Ratings

ABCB

DA Davidson Maintains Buy on Ameris, Raises Price Target to $81

Market-Moving Exclusives

Exclusives

VIVK

EXCLUSIVE: Vivakor Tells Benzinga 'Co has announced the sale of the non-core business units of Meridian Equipment Leasing, LLC, and Equipment Transport, LLC, subsidiaries of Vivakor Transportation, LLC, an indirect wholly-owned subsidiary of the Company'

Macro Economic Events

Econ #s

Economics

USA Core PCE Prices (Q2) 2.5% Vs 2.4% Est

EXCLUSIVE: Vivakor Tells Benzinga Co. Unlocks $59M In Debt Reduction And Improves Profitability With Strategic Sale of Non-Core Business Units

Macro Notification

General

US GDP (QoQ) (Q2) +3% vs +2.5% Est.

DA Davidson analyst Manuel Navas maintains Eagle Financial Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSI#NASDAQ">EFSI</a>) with a Buy and raises the price target from $39 to $40.

EFSI

DA Davidson Maintains Buy on Eagle Financial Services, Raises Price Target to $40

Fortive (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ftv#NYSE">FTV</a>) expects FY 2025 Adj EPS of $2.50 to $2.60 from continuing operations of $2.50-$2.60 vs $2.60 Est
Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) expects FY 2025 Adj EPS of $2.50 to $2.60 from continuing operations of $2.50-$2.60 vs $2.60 Est

Guidance

CORRECTION: Fortive Expects FY 2025 Adj EPS Of $2.50 To $2.60 From Continuing Operations Of $2.50-$2.60 Vs $2.60 Est

-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer's disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CETP inhibition as a potential novel, upstream approach to Alzheimer's prevention –
-- In APOE4/E4 carriers, the highest risk category for Alzheimer's disease, obicetrapib reduced p-tau217 levels by 20.5%, over 12 months, compared to placebo (p=0.010) --
-- Results build on obicetrapib's cardiometabolic profile, including multiple clinical trials demonstrating reductions in LDL-C, small dense LDL particles, Lipoprotein(a), and biomarkers associated with diabetes and kidney function –
NAARDEN, the Netherlands and MIAMI, July 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced full data from the prespecified Alzheimer's disease ("AD") biomarker analysis in the BROADWAY clinical trial (NCT05142722). The data were presented today during a Developing Topics oral session at the 2025 Alzheimer's Association International Conference ("AAIC") in Toronto.
The BROADWAY trial was primarily designed as a pivotal Phase 3 trial to evaluate LDL-C lowering efficacy of obicetrapib, a potent CETP inhibitor, in adult patients with established atherosclerotic cardiovascular disease ("ASCVD") and/or heterozygous familial hypercholesterolemia ("HeFH"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. In connection with this trial, a prespecified analysis evaluated the effect of obicetrapib on plasma biomarkers of AD in 1,515 patients with established ASCVD and/or HeFH whose ApoE status was able to be determined, including 367 ApoE4 carriers. Safety in this population was not evaluated independently from the overall BROADWAY study population, where obicetrapib was observed to be well-tolerated, with safety results comparable to placebo.
ApoE4 is both a risk factor for CVD and AD where ApoE4 carriers generally exhibit higher levels of LDL-C, Lp(a), and reduced cholesterol transport and clearance. Treatment with obicetrapib 10 mg daily for 12 months resulted in statistically significant lower absolute changes in plasma p-tau217, a key biomarker of AD pathology, in both the analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215). Favorable trends were also observed across additional biomarkers, including neurofilament light chain ("NFL"), glial fibrillary acidic protein ("GFAP"), p-tau181, and the Aβ42/40 ratio, in the full analysis set and in ApoE4 carriers, with the greatest effect generally observed in carriers of two E4 proteins.&nbsp;&nbsp;

Biotech

NAMS

NewAmsterdam's Obicetrapib Reduces Alzheimer's Biomarker p-tau217 In High-Risk ApoE4 Carriers, Supporting CETP Inhibition As Potential Preventive Approach

Abacus Global Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) ("Abacus" or the "Company"), a leader in the alternative asset management space, today announced the expiration and results of its previously announced exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its (i) outstanding public warrants (the "public warrants") and (ii) outstanding private placement warrants (the "private placement warrants" and, together with the public warrants, the "warrants") to purchase shares of common stock, par value $0.0001 per share, of the Company ("common stock"). The Offer and Consent Solicitation expired at 11:59 p.m., Eastern Time, on July 29, 2025.
The Company has been advised that 18,188,277 warrants (including 500 warrants tendered through guaranteed delivery), or approximately 88% of the outstanding warrants, were validly tendered and not validly withdrawn prior to the expiration of the Offer and Consent Solicitation. The Company expects to accept all validly tendered warrants for exchange and settlement on or before July 30, 2025. In addition, pursuant to the Consent Solicitation, the Company received the approval of parties representing approximately 83% of the outstanding public warrants and approximately 94% of the outstanding private placement warrants to amend the warrant agreement that governs the warrants (such amendment, the "Warrant Amendment"), which exceeds the threshold of 50% of the outstanding public warrants required to effect the Warrant Amendment. Accordingly, the Company and Continental Stock Transfer &amp; Trust Company entered into the Warrant Amendment, dated July 30, 2025, and the Company expects to&nbsp;exercise its right, in accordance with the terms of the Warrant Amendment, to exchange each warrant that is outstanding upon the closing of the Offer for 0.207 shares of common stock per warrant, which is a ratio 10% less than the exchange ratio applicable to the Offer (the "Post-Offer Exchange").
The Company engaged SG Americas Securities, LLC as the dealer manager for the Offer and Consent Solicitation, D.F. King &amp; Co., Inc. as the information agent for the Offer and Consent Solicitation, and Continental Stock Transfer &amp; Trust Company served as the exchange agent for the Offer and Consent Solicitation.

Abacus Global Management Announces 88% Warrant Exchange Participation, Moves Forward With Warrant Amendment And Post-Offer Exchange

New direct bank-to-wallet link, Chase Ultimate Rewards transfer, and the ability to use Chase credit cards, will give users more ways than ever to get into crypto
Today, JPMorganChase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) announced a strategic partnership that sets a new standard for customer choice and security in the innovation economy. This collaboration introduces features designed to enhance access and optionality for our mutual customers.
The initial phase of the partnership includes new features for mutual customers, including:
<ul>
<li>Direct Bank-to-Wallet Connection: Through JPMorgan's secure API, Chase customers will be able to seamlessly link their bank accounts to Coinbase wallets. This direct connection will help mutual customers transact with the confidence, security, and privacy they're used to as customers of Chase.</li>
<li>Transfer of Chase Ultimate Rewards Points: Chase customers will be able to transfer their Chase Ultimate Rewards points to their Coinbase Account at one-to-one redemption ratio (100 points equals $1.00 in redemption value). This marks the first time a major credit card rewards program will be used to fund a crypto wallet.</li>
<li>Beginning this Fall, the ability to use Chase credit cards on Coinbase: For the first time,customers will have the ability to fund their Coinbase accounts using Chase credit cards.</li>
</ul>
We expect these direct bank-to-wallet and Ultimate Rewards features to go live in 2026, and the ability to use credit cards to fund a Coinbase account in Fall 2025.

COIN

JPMorgan And Coinbase Partner To Launch Direct Bank-To-Wallet Transfers, Chase Rewards-To-Crypto Conversions, And Credit Card Funding

<a href="https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/" title="https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/">https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/</a>

'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News

DA Davidson analyst Rudy Kessinger maintains CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) with a Buy and raises the price target from $200 to $220.

CVLT

DA Davidson Maintains Buy on CommVault Systems, Raises Price Target to $220

IXHL

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

DA Davidson analyst Rudy Kessinger maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Neutral and raises the price target from $47 to $50.

VRNS

DA Davidson Maintains Neutral on Varonis Systems, Raises Price Target to $50

<a href="https://www.wsj.com/business/media/amazon-to-pay-new-york-times-at-least-20-million-a-year-in-ai-deal-66db8503" title="https://www.wsj.com/business/media/amazon-to-pay-new-york-times-at-least-20-million-a-year-in-ai-deal-66db8503">https://www.wsj.com/business/media/amazon-to-pay-new-york-times-at-least-20-million-a-year-in-ai-deal-66db8503</a>

AMZN

'Amazon To Pay New York Times At Least $20 Million A Year In AI Deal; The Multiyear Deal Lets Amazon Use Content From The Times's News And Cooking Sections And The Athletic' - WSJ

Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) with a Buy and raises the price target from $8 to $11.

Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11

CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.80 by 10.41 percent. This is a 62.96 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $328.000 million which beat the analyst consensus estimate of $316.088 million by 3.77 percent. This is a 45.97 percent increase over sales of $224.706 million the same period last year.

Earnings

Earnings Beats

CYBR

CyberArk Software Q2 Adj. EPS $0.88 Beats $0.80 Estimate, Sales $328M Beat $316.088M Estimate

TEVA

During Conf Call, Teva Pharmaceutical CFO Reportedly Says Confirmed U.S. Tariffs Are Absorbed Into 2025 Non-GAAP Outlook

Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) reported quarterly sales of $672.663 million which beat the analyst consensus estimate of $646.534 million by 4.04 percent. This is a 3.84 percent increase over sales of $647.806 million the same period last year.

Earnings Misses

ETSY

CORRECTION: Etsy Q2 Sales $672.663M Beat $646.534M Estimate

MSTU And MSTZ: The Only 2x ETFs On MicroStrategy And One Of The Most Volatile Ways To Play Bitcoin

MSTZ

Screenshot 2024-10-11 at 5.33.57 PM

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ETFs

ETF Opportunities Trust T-Rex 2X Inverse MSTR Daily Target ETF

Comments

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF

Noticias

Últimas noticias sobre ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF (BATS:MSTU)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL